A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (Q113890883)
Jump to navigation
Jump to search
clinical trial
Language | Label | Description | Also known as |
---|---|---|---|
English | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer |
clinical trial |
Statements
ADEPT (English)
0 references
20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT) (English)
0 references
11 January 2021
0 references
1 September 2026
0 references
375
0 references
18 year
0 references